Roche Sues Mylan Over Generic Xeloda ANDA

Law360, New York (April 14, 2009, 12:00 AM EDT) -- Hoffmann-La Roche Inc. has sued generic-drug manufacturer Mylan Pharmaceuticals Inc. for allegedly infringing a patent for the oral chemotherapy drug Xeloda after learning of Mylan's intent to make and sell a generic version of the cancer treatment.

Roche lodged the suit April 8 in the U.S. District Court for the District of New Jersey, claiming that Mylan infringed the patent by seeking U.S. Food and Drug Administration approval to market 150 mg and 500 mg generic versions of Roche’s Xeloda-brand capecitabine tablets prior to the expiration...
To view the full article, register now.